BG Medicine, a life sciences company focused on the discovery, development, and commercialization of novel cardiovascular diagnostics, announced that it has signed an agreement with Kindstar Diagnostics Co. Ltd., the largest esoteric diagnostic testing business in China, enabling Kindstar to offer galectin-3 testing services for heart failure management in China. In the US, the BGM Galectin-3(NYSE:R) test is cleared by the FDA as an aid in assessing the prognosis of patients with chronic heart failure.
Kindstar, a company that provides esoteric diagnostic testing services to hospitals and physicians in every province of China and provides laboratory testing services to over 2,000 Chinese hospitals, will offer galectin-3 testing services as part of its growing suite of cardiovascular tests. Kindstar has a broad reach and strong network in the burgeoning diagnostic testing market of China, which is in the process of reforming its health care system under its Healthy China 2020 initiative. While the country works to expand health care coverage for its 1.4 billion citizens, a substantial and increasing segment of the population currently pay out-of-pocket for essential medical services, which provides a ready market for diagnostic testing services like galectin-3 testing.
"We are excited to be partnering with Kindstar, the largest diagnostics lab in China, to further expand the footprint of galectin-3 testing throughout the world," said Eric Bouvier, President and Chief Executive Officer of BG Medicine. "Cardiovascular disease is one of the most prevalent and debilitating diseases in China, affecting more than 230 million people, and we believe that Kindstar's galectin-3 testing services will help to provide medical professionals with clinical information on fibrosis formation and cardiac remodeling, which are important biological processes in the development and progression of heart failure, while also helping to manage the costs of expanding health care coverage to more of China's citizens."
"Every minute six people in China die from cardiovascular disease, making it imperative that we do what we can to improve the lives of those affected," said Dr. Shiang Huang, Chief Executive Officer of Kindstar Diagnostics. "We believe that clinically relevant and novel markers like galectin-3 will help medical professionals in China identify patients who are at greatest risk for developing heart failure, which assists us to focus the most attention on those who need it."
In addition to this agreement with Kindstar in China, BG Medicine has marketing and distribution agreements with leading national and regional testing facilities in the United States, including Health Diagnostics Laboratory, Laboratory Corporation of America, Cleveland Heart Laboratory, Mayo, Atherotech and ARUP. BG Medicine has also partnered with leading diagnostic instrument manufacturers, including Abbott Laboratories, Alere, bioMerieux and Siemens, for the development and commercialization of automated versions of galectin-3 testing.
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html